Poland· PL-100508525
Cerdelga
A eliglustat product containing eliglustatum, registered in Poland by Sanofi B.V.. The same ATC class is registered in 17 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Eliglustat is registered in 17 of 19 countries.
Countries holding a registration under ATC A16AX10 (eliglustat), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 11 of them publish a price we can compare per daily dose
Eliglustat · ATC A16AX10
17 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of eliglustat costs, country by country.
Normalised to the WHO defined daily dose (0.168 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Eliglustat · price per daily dose (0.168 g)
USD · FX 28 Sept 2026
- CH Switzerland$1116.28
The record
At a glance
URPL (Poland)- Active substance
- Eliglustatum
- Manufacturer
- Sanofi B.V.
- Country
- Poland (PL)
- ATC code
- A16AX10
- ATC class
- Eliglustat
- Defined daily dose
- 0.168 g, O
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin05909991559182
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
336 interactions on record for eliglustat.
Graded by severity as the source publishes them — 119 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Eliglustat · interactions on record
336 records
- 119 severe
- 210 moderate
- 7 minor
Most severe, free to view
- ClotrimazoleA01AB18severe
- CimetidineA02BA01severe
- DiphenhydraminA04AB05severe
- AprepitantA04AD12severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Eliglustat in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumCerdelga 21 mgSanofi
- CzechiaCERDELGASanofi B.V., Amsterdam
- FinlandCerdelgaSanofi B.V.
- IrelandCerdelga 21mg Hard capsuleSanofi B.V.
- IcelandCerdelgaSanofi B.V.
- NetherlandsCerdelga 21 mg harde capsulesSanofi B.V.
- SwedenCerdelga 21 mg Kapsel, hårdSanofi B.V.
- SwitzerlandCerdelga
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Cerdelga
- Liechtenstein · Cerdelga
- Norway · Cerdelga
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d9f1840f-1773-45d5-9e70-06cb2faea836 GET /v1/drugs/d9f1840f-1773-45d5-9e70-06cb2faea836?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Kapsułki twarde",
"source": "urpl",
"strength": "21 mg",
"packaging": "05909991559182 ¦ Rpz ¦ EU/1/14/974/004 ¦ 158990\n56 kaps.",
"substance": "Eliglustatum 21 mg",
"common_name": "Eliglustatum",
"pl_product_id": "100508525",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about eliglustat.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.